A Double-Blind, Multicenter, Parallel-Group Study of Paroxetine, Desipramine, or Placebo in Breast Cancer Patients (stages I, II, III, and IV) With Major Depression

Musselman, Dominique L.; Somerset, Wendy; Guo, Ying; Manatunga, Amita K.; Porter, Maryfrances R.; Penna, Suzanne; Lewison, Barbara; Goodkin, R.S.; Lawson, Kathryn C.; Lawson, David H.; Evans, Dwight L.; Nemeroff, Charles B.

doi:10.4088/jcp.v67n0217

Cited by 79 publications

(53 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In conclusion, the results of this study confirm previous evidence on the efficacy and safety of paroxetine in the treatment of depressed cancer patients [38][39][40][41][42][43][44]. Going further than previous studies, our results suggest that slow titration is better tolerated than standard paroxetine titration for the treatment of depression in cancer patients.…”

Section: Resultssupporting

confidence: 87%

Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study

Amodeo

Castelli

Leombruni

et al. 2011

Support Care Cancer

View full text Add to dashboard Cite

show abstract

Section: Resultssupporting

confidence: 87%

Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study

Amodeo

Castelli

Leombruni

et al. 2011

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…Mean changes in Hamilton depression and anxiety scale scores, and CGI-S scores, the primary efficacy measures, were not significantly different for the paroxetine and desipramine groups than those for the placebo treated group. The small sample size limits interpretation of these data, suggesting need for further studies (178).…”

Section: Antidepressant Treatments For Specific Diagnostic Groupsmentioning

confidence: 96%

Medical Co-Morbidity in Depressive Disorders

Benton

Staab

Evans

2007

Annals of Clinical Psychiatry

Self Cite

137

View full text Add to dashboard Cite

Background. Depression is much more prevalent among those with chronic medical conditions compared to the general population of the United States. Depression is recognized as a cause of increased morbidity and mortality and has been associated with higher health care costs, adverse health behaviors, significant functional impairment, lost work productivity, occupational disability and increased health care utilization. Method. Searches of Medline, OVIDMedline, PubMed and PsycINFO of all English-language articles published between 1966 and 2007 were conducted using the keywords mood disorders, medical comorbidity, depression, antidepressant therapy. Supplemental references were manually extracted from relevant articles and chapters. Reviews of mechanistic studies and open label and randomized controlled trials of depression in patients with medical co morbidities were reviewed. Results. Depressive disorders are prevalent among the medically ill and the relationship between depression and medical illness may be bidirectional. Antidepressant medications are effective in the treatment of depression in the medically ill. Conclusions. Depressive disorders can adversely impact the course of medical illnesses. Available antidepressant treatments are effective for the treatment of depression in the medically ill. Early identification and treatment of depression in medical illness can positively influence medical outcomes and quality of life.

show abstract

“…Many physicians prescribe short-term benzodiazepines to help patients cope with the situational anxiety associated with surgery, chemotherapy or radiation (144). There are relatively few placebocontrolled drug trials in patients with depression and cancer (12,(145)(146)(147)(148)(149)(150)(151) and virtually none focusing on anxiety disorders. Nonetheless, the traditional antidepressants [e.g., TCAs, SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs)] possess anxiolytic properties, and some studies demonstrated improvement in anxiety symptoms in patients with a primary diagnosis of depression (144,148).…”

Section: N F L U E N T I a L P U B L I C A T I O N Smentioning

confidence: 99%

Anxiety Disorders and Comorbid Medical Illness

Roy‐Byrne¹,

Davidson²,

Kessler³

et al. 2008

FOC

View full text Add to dashboard Cite

Objective:To provide an overview of the role of anxiety disorders in medical illness. Method: The Anxiety Disorders Association of America held a multidisciplinary conference from which conference leaders and speakers reviewed presentations and discussions, considered literature on prevalence, comorbidity, etiology and treatment, and made recommendations for research. Irritable bowel syndrome (IBS), asthma, cardiovascular disease (CVD), cancer and chronic pain were reviewed. Results: A substantial literature supports clinically important associations between psychiatric illness and chronic medical conditions. Most research focuses on depression, finding that depression can adversely affect self-care and increase the risk of incident medical illness, complications and mortality. Anxiety disorders are less well studied, but robust epidemiological and clinical evidence shows that anxiety disorders play an equally important role.Biological theories of the interactions between anxiety and IBS, CVD and chronic pain are presented. Available data suggest that anxiety disorders in medically ill patients should not be ignored and could be considered conjointly with depression when developing strategies for screening and intervention, particularly in primary care. Conclusions:Emerging data offer a strong argument for the role of anxiety in medical illness and suggest that anxiety disorders rival depression in terms of risk, comorbidity and outcome. Research programs designed to advance our understanding of the impact of anxiety disorders on medical illness are needed to develop evidence-based approaches to improving patient care. (Reprinted with permission from General Hospital Psychiatry 2008; 30:208 -225)

show abstract

A Double-Blind, Multicenter, Parallel-Group Study of Paroxetine, Desipramine, or Placebo in Breast Cancer Patients (stages I, II, III, and IV) With Major Depression

Cited by 79 publications

References 17 publications

Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study

Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study

Medical Co-Morbidity in Depressive Disorders

Anxiety Disorders and Comorbid Medical Illness

Contact Info

Product

Resources

About